New Delhi|HL
Zydus Cadila has received final approval from the USFDA to market Mycophenolate mofetil for injection used in organ transplants to prevent rejection.
While filing the BSE the company stated that approval is for Mycophenolate Mofetil injection of strength 500mg/vial
The drug is indicated for use in combination with other drugs — cyclosporine and corticosteroids for prophylaxis of organ rejection in patients receiving kidney, liver or heart transplants, it added.
It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad, the company said.
Zydus cadila is Cadila Healthcare
